[go: up one dir, main page]

WO2013173583A8 - Inhibiteurs de psma - Google Patents

Inhibiteurs de psma Download PDF

Info

Publication number
WO2013173583A8
WO2013173583A8 PCT/US2013/041353 US2013041353W WO2013173583A8 WO 2013173583 A8 WO2013173583 A8 WO 2013173583A8 US 2013041353 W US2013041353 W US 2013041353W WO 2013173583 A8 WO2013173583 A8 WO 2013173583A8
Authority
WO
WIPO (PCT)
Prior art keywords
psma inhibitors
compounds
psma
methods
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/041353
Other languages
English (en)
Other versions
WO2013173583A1 (fr
Inventor
Clifford BERKMAN
Svetlana A. STEKHOVA
Holger Siebeneicher
Keith Graham
Ralf Lesche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of WO2013173583A1 publication Critical patent/WO2013173583A1/fr
Publication of WO2013173583A8 publication Critical patent/WO2013173583A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés tels que définis dans la description qui sont utiles dans (1) des méthodes de diagnostic permettant la détection et/ou l'identification de cellules présentant l'antigène prostatique spécifique membranaire (PSMA); et (2) des procédés de préparation desdits composés.
PCT/US2013/041353 2012-05-16 2013-05-16 Inhibiteurs de psma Ceased WO2013173583A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647929P 2012-05-16 2012-05-16
US61/647,929 2012-05-16
US201361779779P 2013-03-13 2013-03-13
US61/779,779 2013-03-13

Publications (2)

Publication Number Publication Date
WO2013173583A1 WO2013173583A1 (fr) 2013-11-21
WO2013173583A8 true WO2013173583A8 (fr) 2014-02-06

Family

ID=48534496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/041353 Ceased WO2013173583A1 (fr) 2012-05-16 2013-05-16 Inhibiteurs de psma

Country Status (1)

Country Link
WO (1) WO2013173583A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014228233B2 (en) * 2013-03-15 2019-02-28 Cancer Targeted Technology Llc 18F-labeled PSMA-targeted pet imaging agents
LT3481804T (lt) 2016-06-10 2025-02-25 The Johns Hopkins University Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė
WO2018031809A1 (fr) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Inhibiteurs chélatés du psma
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
IL307381A (en) 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1999136T3 (pl) 2006-03-14 2013-03-29 Cancer Targeted Tech Llc Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
US9328129B2 (en) * 2010-11-12 2016-05-03 Washington State University Peptidomimetic inhibitors of PSMA
ES2657863T3 (es) * 2011-06-15 2018-03-07 Cancer Targeted Technology Llc Inhibidores quelados de PSMA

Also Published As

Publication number Publication date
WO2013173583A1 (fr) 2013-11-21

Similar Documents

Publication Publication Date Title
IL257714B (en) Systems and methods for the analysis of multiple analytes
EP3965111B8 (fr) Méthodes d'analyse génomique
WO2012075075A3 (fr) Procédés et systèmes destinés à identifier spatialement des cellules anormales
EP3608021A3 (fr) Dispositifs de détection d'analytes, dispositifs multiplex et de type comptoir pour la détection d'analytes et leurs utilisations
WO2012106385A3 (fr) Procédés d'identification de multiples épitopes dans des cellules
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2013134503A3 (fr) Procédés et compositions pour détecter de multiples analytes avec un seul signal
EP2852687A4 (fr) Procédés de préparation d'un échantillon
WO2012048340A3 (fr) Séquençage immunitaire à haut débit
WO2015013465A3 (fr) Méthodes et compositions de détection d'une contamination bactérienne
EP3486657A3 (fr) Dispositif et methodes pour le diagnostic du cancer du pancréas
EP2729464B8 (fr) 1,3-thiazépines à cyclopropyle fusionné en tant qu'inhibiteurs de bace 1 et/ou de bace 2
EP4563709A3 (fr) Méthodes et matériaux pour évaluer le déséquilibre allélique
EP2741032A3 (fr) Réfrigérateur et son procédé de fonctionnement
EP2566975A4 (fr) Procédés de criblage, compositions identifiées par ce procédé, outils utiles pour leur identification et populations cellulaires ainsi produites
ZA201400331B (en) Glyphosate tolerant corn event vco-o1981-5 and kit and method for detecting the same
EP2565618A3 (fr) Testeur de dureté
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
EP2881742B8 (fr) Dispositif d'analyse automatique
WO2013173583A8 (fr) Inhibiteurs de psma
WO2013166153A3 (fr) Procédés et compositions pour le diagnostic du cancer
HK1204061A1 (en) Methods and kits for detecting and diagnosing neurotrauma
UY34405A (es) Películas de poliolefina y poli (ácido láctico) que contienen porosidad y sorbentes.
EP2559539A4 (fr) Calandre à des fins d'essai
PL2879542T3 (pl) Sposób sprawdzania monety

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13725522

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13725522

Country of ref document: EP

Kind code of ref document: A1